Grants & Projects per year
Personal profile
Fingerprint
Dive into the research topics where Charles Berenson is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
IPA for Jeffrey Miecznikowski
Berenson, C. (PI)
Veterans Admin Western New York Healthcare Systems
10/6/25 → 09/30/26
Project: Research
-
IPA - Lorrie Mandell
Berenson, C. (PI)
Veterans Admin Western New York Healthcare Systems
12/2/24 → 09/30/26
Project: Research
-
VA IPA for Lori Grove 25-26
Berenson, C. (PI)
Veterans Admin Western New York Healthcare Systems
01/6/25 → 01/31/25
Project: Research
-
IPA - Lori Grove
Berenson, C. (PI)
Veterans Admin Western New York Healthcare Systems
10/1/23 → 12/31/24
Project: Research
-
IPA J. Miecznikowski
Berenson, C. (PI)
Veterans Admin Western New York Healthcare Systems
07/1/23 → 06/30/25
Project: Research
-
Comparability of Gastrointestinal Microbiome and Bile Acid Profiles in Patients With First or Multiply Recurrent Clostridioides difficile Infection
Bryant, J. A., Straub, T. J., Pardi, D. S., Litcofsky, K. D., Kelly, C. R., Chafee, M. E., Cohen, S. H., Khanna, S., Berenson, C. S., Wortman, J., Sims, M., Ford, C. B., Lombardo, M. J., McGovern, B. H., Von Moltke, L., Kraft, C. S., Henn, M. R. & Hasson, B. R., Nov 15 2025, In: Journal of Infectious Diseases. 232, 5, p. e733-e740Research output: Contribution to journal › Article › peer-review
Open Access4 Scopus citations -
Correction to: Integrated Safety and Efficacy Analyses of Phase 3 Trials of a Microbiome Therapeutic for Recurrent CDI (Infectious Diseases and Therapy, (2024), 13, 10, (2105-2121), 10.1007/s40121-024-01007-z)
on behalf of the ECOSPOR III and ECOSPOR IV investigators, Oct 2024, In: Infectious Diseases and Therapy. 13, 10, p. 2209-2210 2 p.Research output: Contribution to journal › Comment/debate
Open Access -
Integrated Safety and Efficacy Analyses of Phase 3 Trials of a Microbiome Therapeutic for Recurrent CDI
on behalf of the ECOSPOR III and ECOSPOR IV investigators, Oct 2024, In: Infectious Diseases and Therapy. 13, 10, p. 2105-2121 17 p.Research output: Contribution to journal › Article › peer-review
Open Access6 Scopus citations -
Recurrent Salmonella bacteraemia and right internal iliac artery endarteritis in a splenectomised patient
Siddiqui, N. N. & Berenson, C. S., Jul 10 2024, In: BMJ Case Reports. 17, 7, e256953.Research output: Contribution to journal › Article › peer-review
-
Assessment of Quality of Life Among Patients With Recurrent Clostridioides difficile Infection Treated with Investigational Oral Microbiome Therapeutic SER-109 Secondary Analysis of a Randomized Clinical Trial
Garey, K. W., Jo, J., Gonzales-Luna, A. J., Lapin, B., Deshpande, A., Wang, E., Hasson, B., Pham, S. V., Huang, S. P., Reese, P. R., Wu, H., Hohmann, E., Feuerstadt, P., Oneto, C., Berenson, C. S., Lee, C., McGovern, B. & vonMoltke, L., Jan 2023, In: JAMA Network Open. 6, 1, e2253570.Research output: Contribution to journal › Article › peer-review
Open Access25 Scopus citations